Soluble and membrane-bound adenylate kinase and nucleotidases augment ATP-mediated inflammation in diabetic retinopathy eyes with vitreous hemorrhage by Zeiner, Julian et al.
ORIGINAL ARTICLE
Soluble and membrane-bound adenylate kinase and nucleotidases
augment ATP-mediated inflammation in diabetic retinopathy eyes
with vitreous hemorrhage
Julian Zeiner1,2 & Sirpa Loukovaara3 & Karolina Losenkova1 &Mariachiara Zuccarini1 & AniM. Korhonen4 & Kaisa Lehti4,5 &
Anu Kauppinen6 & Kai Kaarniranta7,8,9 & Christa E. Müller2 & Sirpa Jalkanen1 & Gennady G. Yegutkin1
Received: 30 July 2018 /Revised: 23 November 2018 /Accepted: 17 December 2018 /Published online: 7 January 2019
# The Author(s) 2019
Abstract
ATP and adenosine are important signaling molecules involved in vascular remodeling, retinal function, and neurovascular
coupling in the eye. Current knowledge on enzymatic pathways governing the duration and magnitude of ocular purinergic
signaling is incompletely understood. By employing sensitive analytical assays, this study dissected ocular purine homeostasis as
a complex and coordinated network. Along with previously characterized ecto-5′-nucleotidase/CD73 and adenylate kinase
activities, other enzymes have been identified in vitreous fluids, including nucleoside triphosphate diphosphohydrolase
(NTPDase), adenosine deaminase, and alkaline phosphatase. Strikingly, activities of soluble adenylate kinase, adenosine deam-
inase, ecto-5′-nucleotidase/CD73, and alkaline phosphatase, as well as intravitreal concentrations of ATP and ADP, were con-
currently upregulated in patients suffering from diabetic retinopathy (DR) with non-clearing vitreous hemorrhage (VH), when
compared to DR eyes without VH and control eyes operated due to macular hole or pucker. Additional histochemical analysis
revealed selective distribution of key ecto-nucleotidases (NTPDase1/CD39, NTPDase2, ecto-5′-nucleotidase/CD73, and alkaline
phosphatase) in the human sensory neuroretina and optic nerve head, and also in pathological neofibrovascular tissues surgically
excised from patients with advanced proliferative DR. Collectively, these data provide evidence for specific hemorrhage-related
shifts in purine homeostasis in DR eyes from the generation of anti-inflammatory adenosine towards a pro-inflammatory and pro-
angiogenic ATP-regenerating phenotype. In the future, identifying the exact mechanisms by which a broad spectrum of soluble
and membrane-bound enzymes coordinately regulates ocular purine levels and the further translation of purine-converting
enzymes as potential therapeutic targets in the treatment of proliferative DR and other vitreoretinal diseases will be an area of
intense interest.
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& NTPDase, alkaline phosphatase, and adenosine deaminase circulate in human vitreous.
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& Purinergic enzymes are up-regulated in diabetic eyes with vitreous hemorrhage.
& Soluble adenylate kinase maintains high ATP levels in diabetic retinopathy eyes.
& Ecto-nucleotidases are co-expressed in the human retina and optic nerve head.
& Alkaline phosphatase is expressed on neovascular tissues excised from diabetic eyes.
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Introduction
Clear signaling roles for extracellular ATP, ADP, and adeno-
sine have been established in virtually all organs and tissues
[1], including the eye [2, 3]. ATP released from damaged
neurons and activated microglia generally acts as a pro-
inflammatory molecule initiating immunomodulatory, neuro-
degenerative, and hyperemic processes in the eye, which are
mediated via activation of P2X7, P2Y1, and other ligand-
gated (P2X) and G protein-coupled (P2Y) receptor subtypes
co-expressed in the sensory retina and other ocular structures
[2, 4–9]. Another mechanism of ATP action comprises its
ectoenzymatic breakdown into adenosine, which in turn, me-
diates multiple effects (often counteracting to ATP) via bind-
ing to its own nucleoside-selective receptors. A2A and other
subtypes of adenosine receptors were shown to be implicated
in the modulation of the light responses of photoreceptors,
retinal hyperemia, pathological retinal angiogenesis, protec-
tion of neurons from hyper-excitation and glutamate toxicity
[3, 10–13]. Previous research from our and other laboratories
revealed the ability of VF and aqueous humor to maintain
ATP and adenosine at certain characteristic nanomolar levels,
which increase in pathological conditions, such as dry eye
disease [14], glaucoma [2, 12, 15], age-related macular degen-
eration with subretinal hemorrhage [4], and diabetic retinopa-
thy (DR) [16, 17].
DR is the most common microvascular complication of
diabetes worldwide, characterized by visual impairment, vas-
cular leakage, vessel occlusion, neuronal and glial dysfunc-
tions, and cell death in retinal capillaries. The growth of newly
formed abnormally differentiated vessels and non-clearing vit-
reous hemorrhage (VH) are clinical hallmarks in the prolifer-
ative form of DR (PDR) [18–23]. Treatments for the vision-
threatening complications of DR have been greatly improved
over the past decade. However, further development of
preventional and interventional strategies against DR requires
a better understanding of the exact mechanisms underlying
diabetes-induced microvascular, neurodegenerative and in-
flammatory complications.
This study aims to further elaborate the role of purinergic
mechanisms in the pathogenesis of DR. We have identified a
broad spectrum of soluble and membrane-bound enzymes,
which are co-expressed in the human VF, sensory retina and
optic nerve head and coordinately regulate ocular nucleotide
and nucleoside levels via two counteracting, purine-
inactivating and ATP-regenerating, pathways. Furthermore,
data on marked upregulations of intravitreal adenylate kinase
(AK), ecto-5′-nucleotidase/CD73 (eN/CD73), adenosine de-
aminase (ADA), and alkaline phosphatase (ALP) activities
and concurrently elevated ATP/adenosine ratio in DR eyes
with VH provide a sufficient justification for reexamination
of the role of purine homeostasis in the pathogenesis of DR.
Materials and methods
Surgical collection of vitreous samples and PDR
neovascular tissues
A total of 136 DR patients and non-diabetic controls operated
due to a quiescent idiopathic macular hole (MH) or pucker
have been recruited to the original study (Table 1). Signed
informed consent was obtained from each participant before
insertion in the study. Clinical surgical enrollment criteria for
Table 1 Diabetes mellitus, age and gender distribution among the
patients studied
Patients MH/pucker PDR NPDR
n 56 43 37
Males/females 18/38 25/18 24/13
DM1 / DM2 – 28/15 8/29
Age (years) 67.6 ± 0.8 45.3 ± 2.4 64.0 ± 2.3
Duration of DM (years) – 24.0 ± 2.0 (43) 15.5 ± 2.0 (35)
VH/NH 0 / 56 34/9 14/23
Blood HbA1c (%) – 9.3 ± 0.3 (34) 7.6 ± 0.4 (32)
The patients were sub-grouped as follows: non-diabetic eyes operated due
to nonvascular vitreoretinal diseases, including quiescent idiopathic mac-
ular hole (MH) or pucker, as well as the diabetic group comprising of
patients with proliferative (PDR) and non-proliferative (NPDR) forms of
diabetic retinopathy. Prolonged vitreous hemorrhage (>2 months) has
been used as an additional surgical enrolment criteria for distinguishing
between the eyes without (NH) and with (VH) non-clearing hemorrhage.
The levels of glycated hemoglobin A1c (HbA1c) in the whole blood and
data on diabetes mellitus (DM) duration were available for the indicated
patient number, as specified in the parentheses. Data are presented as
mean ± SEM
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diabetic vitrectomy were severe prolonged VH (> 2 months),
traction retinal detachment or severe cystic macular edema
with vitreous traction. VF samples were collected by a
vitreoretinal surgeon at the start of the conventional three-
port pars plana vitrectomy without an infusion of artificial
fluid, as described elsewhere [24]. Additional information on
vitreous collection and processing can be found in the
Supplementary Material. For the preparation of serum, blood
was drawn from the antecubital vein and allowed to clot be-
fore centrifugation (10 min at 1500g). Undiluted vitreous and
serum aliquots were transferred into Eppendorf tubes and im-
mediately frozen and stored at − 70 °C until laboratory analy-
sis. Neovascular specimens were also excised surgically from
vitrectomized eyes of two PDR patients during vitrectomy,
using segmentation and delamination, cut with microscissors,
and removed from the vitreous cavity with intraocular end-
gripping microforceps (MaxGrip Alcon Laboratories), as de-
scribed previously [22]. Extreme care was placed to remove
intact, undamaged neovessels without causing damage to the
optic nerve or temporal vascular arcade. The studies were
conducted according to the principles of the Declaration of
Helsinki and approved by the Institutional Review Board of
the Helsinki University Central Hospital and the Ethical
Committee.
Preparation of human eye and PDR neovascular tissue
sections
Cadaver eyeballs were enucleated 48 h postmortem from a
female donor without apparent eye diseases. The use of hu-
man tissues and organs has been approved by the Ethical
Committee of Turku University Hospital. Transverse sections
of the retrobulbar optic nerve close to the optic nerve head, as
well as neovascular tissues (excised surgically from PDR pa-
tients as described above), were embedded in the cryo-mold
with Tissue-Tek® O.C.T. compound (Sakura Finetek Europe
B.V. The Netherlands), cut using a cryostat and stored at −
80 °C. Eyeballs were additionally enucleated from a 68-year-
old patient having a periocular tumor which was estimated to
be invading to the bulbus. Immediately after the enucleation,
the eyeballs were fixed in 10% formalin for 2–3 days followed
by embedding in paraffin according to a routine protocol.
Experienced pathologists confirmed that the tumor invasion
had not reached the eyeball. The tenets of the Declaration of
Helsinki and Kuopio University Hospital ethical rules were
followed.
Measurement of soluble purine-converting activities
Soluble NTPDase/ADPase, eN/CD73, ADA, and AK were
assayed by incubating the VF (or serum) with [3H]ADP,
[3H]AMP, [3H]adenosine, and [3H]AMP plus ATP, as respec-
tive enzyme substrates. 3H-labeled nucleotides and
nucleosides were separated by thin-layer chromatography
(TLC) and quantified by scintillation β-counting [17, 25] or
developed by autoradiography, as described in the
Supplementary Material. In competitive assays, the samples
were pretreated for 30 min with inhibitors of NTPDases sodi-
um polyoxotungstate-1 (POM-1) (Tocris Bioscience, Bristol,
UK) and POM-144 [26], selective eN/CD73 inhibitors α,β-
methylene ADP (APCP, Sigma) and its derivative N6-
phenylethyl-[(phosphonomethyl)-phosphonic acid], (PSB-
12379 [27]), inhibitor of AK diadenosine pentaphosphate
(Ap5A), and ADA inhibitor erythro-9-(2-hydroxy-3-
nonyl)adenine hydrochloride (EHNA, Tocris Bioscience).
Soluble ALP was assayed by incubating VF (8 μl) on clear
96-well plates in 180 μl of basal salt solution (BSS; compris-
ing 130 mMNaCl, 5 mMKCl, 1.5 mMCaCl2, 1 mMMgSO4,
25 mM HEPES and 5 mM glucose, pH 9.3) in the absence or
presence of a specific ALP inhibitor tetramisole (5 mM). After
a 60-min pre-treatment, 20 μl of chromogenic substrate for
ALP, p-nitrophenyl phosphate (p-NPP), was added to the
microwells at a final concentration of 3 mM, followed by
incubation at 37 °C for 20 h and subsequent measurement of
the absorbance intensity at 405 nm (Tecan Infinite M200,
Salzburg, Austria). Likewise, serum ALP activity was deter-
mined after a 3-h incubation of human serum (2 μl) with
3 mM p-NPP.
Determination of ATP, ADP, adenosine, and HbA1c
Intravitreal purine concentrations were determined by using
bioluminescent (ATP and ADP) and fluorometric (adenosine)
enzyme-coupled purine-sensing assays [28], under the condi-
tions delineated experimentally for VF [16]. After defrosting,
VF samples were immediately heat-inactivated for 5 min at
65 °C, thus preventing further metabolism of endogenous pu-
rines through soluble purinergic enzymes. The protein con-
centration was determined using the BCA Protein Assay Kit
(Pierce, Rockford, IL). Glycated hemoglobin A1c (HbA1c)
was measured in the blood using the Tina-quant® HbA1c
assay kit with the Cobas Integra-800 analyzer (Roche
Diagnostics, Rotkreuz, Switzerland).
Immunohistochemical analysis of ecto-nucleotidases
in the human eye
Formalin-fixed, paraffin-embedded sections of the human ret-
ina were stained for ecto-nucleotidases using UltraView DAB
Detection Kit and BenchMark XT automated slide staining
system (VentanaMedical Systems Inc., Roche, USA), accord-
ing to manufacturer’s instructions. For immunofluorescence
staining, cryosections of the optic nerve head and neovascular
tissues were sequentially incubated with primary and second-
ary fluorescently labeled antibodies. Additional details are
given in the Supplementary Material.
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Enzyme histochemistry
For localization of ecto-nucleotidase activities, a modification
of the lead nitrate methodwas employed [29, 30], as described
in the Supplementary Material. ALP activity was additionally
evaluated by measuring dark purple precipitate after incubat-
ing the tissues at alkaline pH with artificial chromogenic en-
zyme substrates 5-bromo-4-chloro-3-indolyl-phosphate/nitro
blue tetrazolium (BCIP/NBT, 0.35 mM each) [30].
Statistical analysis
Two-tailed paired Student’s t test was used for single compar-
isons and one-way ANOVAwith Dunnett’s multiple compar-
ison post-hoc tests for multiple comparisons. Nonparametric
Spearman’s correlation coefficients were computed to inves-
tigate the inter-correlations of continuous variables. In the case
of comparative studies, the researcher(s) analyzed the encoded
vitreous samples provided by the surgeon in a masked way,
without knowing the clinical status of the patients. The results
were analyzed with Prism GraphPad 7 software (San Diego,
CA) and presented either as column bars (mean ± SEM) or as
box-and-whiskers plots, where the box extends from the 25th
to the 75th percentile with a horizontal line at the median and
with whiskers showing the range of the data. The statistical
significance levels were denoted as *P < 0.05 and **P < 0.01.
Results
A broad network of soluble enzymes co-exists
in human vitreous and regulates intravitreal purine
levels via counteracting, purine-inactivating
and ATP-regenerating, pathways
This study was undertaken to characterize the major purine-
converting pathways in human vitreous. As shown in Fig. 1a,
incubation of VF with [3H]AMP caused its breakdown into
[3H]adenosine (lane 2), and this nucleotidase reaction was
prevented with an eN/CD73 inhibitor, APCP (lane 3). In the
presence of γ-phosphate-donating ATP, part of [3H]AMP was
converted into high-energy 3H-phosphoryls (lane 4), whereas
specific AK inhibitor Ap5A blocked this backward
phosphotransfer reaction (lane 5). Incubation of VF with
[3H]ADP as an initial substrate was accompanied by its
transphosphorylation into [3H]ATP and [3H]AMP (lane 6),
and this catalytic conversion was markedly inhibited in the
presence of Ap5A (lane 7). Adding [
3H]adenosine to the VF
triggered its partial deamination into [3H]inosine (lane 10).
Consistent with the autoradiographic data, a direct
quantitative analysis confirmed the presence of low but
clearly detectable ADPase activity in most of the VF
studied (Fig. 1b). Pre-treatment of the samples with a
non-selective NTPDase inhibitor POM-144 [26], but not
with another inhibitor POM-1, diminished the rate of
[3H]ADP hydrolysis by ~ 50%. Taking into account the
different ATP:ADP hydrolysis ratios for NTPDase1 and
other members of this family, NTPDase2 and NTPDase3
(~ 1:1, 10–40:1 and 3–4:1, respectively) [31, 32] and by
drawing an analogy with soluble NTPDase1/CD39 freely
circulating in the human and murine blood [25], it may
be speculated that NTPDase1/CD39 represents the major
enzyme responsible for the measured [3H]ADP hydroly-
sis in human vitreous. The employment of [3H]AMP as
another tracer substrate demonstrated the presence of
AMPase activity, which can be blocked by eN/CD73
inhibitors, APCP and PSB-12397 (Fig. 1b). In the pres-
ence of γ-phosphate-donating ATP, part of [3H]AMP was
phosphorylated into [3H]ADP/ATP, while Ap5A
prevented this phosphotransfer reaction. For direct quan-
tification of ADA activity, we used a particular solvent
mixture that enabled bet ter TLC separat ion of
[3H]adenosine and its 3H-metabolites [33]. Incubation
of VF with [3H]adenosine caused its deamination into
[3H]inosine, which can be blocked by a specific ADA
inhibitor EHNA (Fig. 1b). Soluble ALP was also deter-
mined spectrophotometrically. Due to the low sensitivity
of this colorimetric technique, the assay settings have
been modified and optimized accordingly, particularly
by incubating the microplate for up to 20 h at alkaline
pH and 37 °C. Long-term incubation of VF with p-NPP
was accompanied by the development of a soluble yel-
low reaction product that may be detected at 405 nm,
and this catalytic reaction was prevented in the presence
of a specific ALP inhibitor, tetramisole (Fig. 1b).
Collectively, the identification of a broad spectrum of
purine-converting enzymes in human VF forms a solid
background for further elucidation of the role of the
ATP-adenosine axis in the pathogenesis of vitreoretinal
diseases in humans.
Soluble eN/CD73, ADA, AK, and ALP activities are
selectively upregulated in diabetic retinopathy eyes
with vitreous hemorrhage
Next, we evaluated the pattern of intravitreal purine homeo-
stasis at pathological states, particularly by comparing PDR
and NPDR patients versus non-diabetic eyes operated due to
MH or pucker. Detailed information on the type of diabetic
mellitus, age and gender distribution among the patients stud-
ied is provided in Table 1. The ability of VF to metabolize 3H-
labeled purines and p-NPP varied substantially among the
individuals. Nevertheless, the activities of eN/CD73
(Fig. 2a), ADA (Fig. 2b) AK (Fig. 2c), and ALP (Fig. 2e),
but not NTPDase/ADPase (Fig. 2d), were increased in VF
from PDR patients, with the first two enzymes being also
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significantly upregulated in NPDR eyes. Additional compar-
ative analysis of the corresponding soluble enzymatic activi-
ties in serum samples from diabetic and non-diabetic patients
did not reveal any differences among the groups studied (Fig.
2a–e; right panels). These data suggest that the observed up-
regulation of intravitreal enzymes occurs locally in DR eyes
and is not accompanied by concurrent shifts in intravascular
purine homeostasis in the systemic circulation. These findings
are consistent with previous observations showing markedly
increased intravitreal AK activities in PDR patients [17], and
further demonstrated that other soluble enzymes (eN/CD73,
ADA, and ALP) also became significantly upregulated in DR
eyes.
We also pooled the obtained AK data with similar activities
determined previously under the same experimental settings
in another cohort of patients operated due to DR (n = 86) and
MH/pucker (n = 31) [17]. This combination allowed us to
perform a more thorough and extended analysis of AK
activities among the diabetic and non-diabetic groups.
Surprisingly, intravitreal AK was shown to be selectively
up-regulated only in DR eyes with severe prolonged VH, with
no gender- or DM type-specific variations in the measured
nucleotide-phosphorylating activities being observed within
the subgroups studied (Supplementary Fig. S1). These data
suggest that VH itself, rather than PDR, serves as a key deter-
mining factor associated with deregulated purine homeostasis
in diabetic eyes. In fact, the performance of a new subgroup
analysis based on this emerging criterion revealed high levels
of eN/CD73, ADA, AK, and ALP in DR eyes with VH, which
significantly exceeded respective soluble activities in DR eyes
without VH and also in non-diabetic controls (Fig. 3a).
Notably, all enzymatic activities were expressed as nanomoles
of substrate(s) converted by 1 ml of fluid per hour. Additional
spectrophotometric analysis did not reveal any differences in
total intravitreal proteins among the groups studied, being
equal to 5.10 ± 0.34 (mean ± SEM; n = 48), 4.94 ± 0.33 (n =
Fig. 1 Competitive analysis of purine-converting pathways in human
vitreous. a VF from macular hole or pucker (MH/Pucker) patients were
pretreated with andwithout APCP andAp5A followed by incubationwith
[3H]adenosine, [3H]ADP, [3H]AMP, and also [3H]AMP with ATP, as
indicated. The blanks (Bl) show the radiochemical purity of tracer sub-
strates in the absence of VF. Mixture aliquots were separated by TLC and
developed by autoradiography. For pictorial illustration, stock solutions
of [3H]ATP, [3H]ADP, [3H]AMP, and [3H]adenosine (~ 1 μl each) were
pooled and separated by TLC (lane 1). The arrows indicate the positions
of 3H-labeled nucleotides, adenosine (Ado), inosine (Ino), and hypoxan-
thine (Hyp), as well as the nonspecific admixture band (Admix) reflecting
partial radiochemical impurity of the commercial [3H]adenosine
preparation. b Vitreous purine-converting activities were quantified by
TLC using [3H]ADP (18 μM), [3H]AMP (80 μM), [3H]AMP (200 μM)
with 400 μM ATP and [3H]Ado (10 μM), as preferred substrates for
NTPDase, eN/CD73, adenylate kinase (AK), and adenosine deaminase
(ADA), respectively. Alkaline phosphatase (ALP) activity was also de-
termined spectrophotometrically using an artificial enzyme substrate p-
NPP (3mM). The samples were pretreated without (Control) and with the
indicated concentrations of certain enzyme inhibitors prior to the addition
of substrates. The ordinates show specific activities expressed as
nanomoles of substrates converted by 1 ml of fluid per hour (mean ±
SEM, n = 4). *P < 0.05 and **P < 0.01, determined by Student’s t test
(paired, two-tailed)
J Mol Med (2019) 97:341–354 345
32) and 5.34 ± 0.16 (n = 56) mg/ml in the DR eyes with and
without VH, as well as control MH/pucker eyes, respectively.
These data allowed excluding the possibility that the revealed
upregulation of soluble enzymatic activities might be due to
the increased amounts of bulk proteins released into the vitre-
ous cavity during VH, vascular leakage, diabetic tractional
retinal detachment, or cell death.
High intravitreal AK correlates with concurrently
upregulated ADA activity and increased levels of ATP
and ADP in DR eyes with VH
By nonparametric correlation analysis, we demonstrated
the existence of a positive correlation between soluble
AK and ADA activities in DR eyes with VH. eN/CD73
correlated with ALP both in diabetic and non-diabetic
eyes and in addition, there was a significant inverse cor-
relation between eN/CD73 and ADA activities in non-
hemorrhagic DR eyes (Fig. 3b, c). Soluble purinergic ac-
tivities were further correlated with ATP, ADP, and aden-
osine levels determined in the same vitrectomized eyes.
Compared to diabetic eyes without VH and non-diabetic
controls, DR eyes with VH were shown to maintain sig-
nificantly increased ATP and ADP, as well as diminished
adenosine concentrations (Fig. 4a and Supplementary
Fig. 2S). Nonparametric correlation analysis demonstrated
the existence of highly positive correlations between AK
activity and intravitreal ATP and ADP levels in DR eyes
with VH (Fig. 4b; Supplementary Fig. S3). Performance
of a similar analysis for eN/CD73 revealed significant
inverse correlations between this soluble nucleotidase
and ATP and ADP levels in DR eyes without VH (Fig.
4b; Supplementary Fig. S4). The interrelations between
other soluble enzymes, ADA, and ALP, and intravitreal
purines were relatively modest or insignificant both in
DR and non-diabetic groups (Fig. 4b; Supplementary
Figs. S5 and S6).
Immunohistochemical analysis reveals the selective
distribution of key ecto-nucleotidases and ALP
within the human sensory retina, PDR neovascular
tissues, and optic nerve head
The current study was also aimed to characterize the distribu-
tion of major ecto-nucleotidases in the sensory retina and in
this way, to establish a link between soluble and membrane-
associated enzymes in the human eye. The presence of dark
retinal pigmented epithelium (RPE) partially interferes with
immunohistochemistry of the eye. Nevertheless, clear-cut dif-
ferences in staining intensities were detected in the presence of
antibodies against different nucleotidases (Fig. 5a–d), as com-
pared with isotype-matched controls (Fig. 5e). In particular,
eN/CD73 was shown to be expressed in the rod-and-cone-
containing photoreceptor cells (Fig. 5a). The results also dem-
onstrated selective compartmentalization of NTPDase1/CD39
(Fig. 5b), NTPDase2 (Fig. 5c), and ALP (Fig. 5d) in the
neouroretinal and subretinal layers, including ganglion cells,
blood vessels, choriocapillaris, and RPE.
Cryosections of the neovascular tissues surgically ex-
cised from two PDR eyes during vitrectomy, as well as
the prelaminar region of the cadaver optic nerve head were
Fig. 2 Analysis of soluble purine-converting activities in the vitreous
fluids and sera from diabetic and non-diabetic patients. Specific ecto-5′-
nucleotidase/CD73 (eN/CD73; a), adenosine deaminase (ADA; b), ade-
nylate kinase (AK; c), NTPDase/ADPase (D), and alkaline phosphatase
(ALP; e) activities were determined in the VF and serum samples collect-
ed from diabetic patients with non-proliferative (NPDR) and proliferative
(PDR) forms of diabetic retinopathy, as well as control non-diabetic pa-
tients operated due to macular hole or pucker (MH/Puck). Purine-
converting enzymes were assayed either by TLC with 3H-labeled purine
substrates (a–d) or spectrophotometrically using the artificial ALP sub-
strate p-NPP (e). Enzymatic activities are presented as box-and-whiskers
plots expressed as nanomoles of substrates converted by 1 ml of fluid per
hour. *P < 0.05 and **P < 0.01, determined by one-way ANOVA with
Dunnett’s multiple comparison test
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also analyzed using enzyme (immuno)histochemistry.
Measurement of ecto-nucleotidase and ALP activities, in
combination with immunofluorescence staining, allowed
us to pinpoint the distribution of key nucleotide-
inactivating enzymes within the tissues. Incubation of
neovascular tissues with BCIP/NBT (known as preferred
chromogenic substrates for ALP [30]) revealed the devel-
opment of dark blue precipitates in the connective tissues
(Fig. 5f). Likewise, fairly similar staining patterns were
observed by staining the tissues with an anti-ALP antibody
(Fig. 5f; rightmost panels). Though, lead nitrate-based en-
zyme histochemistry did not detect any ecto-nucleotidase
activities in the tissues studied (data not shown).
Incubation of the optic nerve head with BCIP/NBT
revealed the development of blue staining in the pia mater
and blood vessels, which was prevented after pre-treating
the sections with an ALP inhibitor tetramisole (Fig. 6b).
Furthermore, we have demonstrated the presence of high
ATP- and ADP-hydrolysing activities in the central retinal
artery and other blood vessels (Fig. 6c), and further iden-
tified NTPDase1/CD39 as a major enzyme responsible for
these nucleotidase reactions (Fig. 6d). The ADPase reac-
tion product can also be seen, albeit faintly in comparison
with ATP, in bundles of the optic nerve fibers (Fig. 6b),
thus suggesting the presence of another ATP-inactivating
enzyme, NTPDase2. Immunofluorescence staining
Fig. 3 Soluble purine-converting activities are selectively up-regulated in
diabetic eyes with vitreous hemorrhage. a Intravitreal eN/CD73, ADA,
AK, NTPDase/ADPase, and ALP activities were determined in DR eyes
without (−) and with (+) VH, as well as from non-diabetic eyes operated
due to macular hole or pucker (MH/P). Enzymatic activities are expressed
as nanomoles of substrates converted by 1 ml of fluid per hour and
presented as box-and-whiskers plots. *P < 0.05 and **P < 0.01, deter-
mined by one-way ANOVA with Dunnett’s multiple comparison test.
(b) Soluble purinergic activities were further correlated with each other.
The most significant interrelations were observed by plotting ADAversus
AK and eN/CD73, as well as ALP versus CD73 activities. The graphs
display enzymatic activities determined in individual patients, as well as
best-fit linear regression lines with 95% confidence intervals. Panel C
summarizes the Spearman’s correlation coefficients (Spearman r) com-
puted to investigate the relationships between the indicated enzymes
measured both in diabetic and non-diabetic eyes. *P < 0.05 and
**P < 0.01, determined by the nonparametric two-tailed correlation
analysis
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confirmed that nerve bundle-surrounding microglial cells
express NTPDase2 (Fig. 6e). Enzyme histochemistry as-
say with AMP (Fig. 6c), together with an eN/CD73 stain-
ing (Fig. 6d, e) revealed that the expression of eN/CD73
in the optic nerve was associated with the meningeal
sheath and the connective tissue septa surrounding blood
vessels and nerve bundles. These protein localization re-
sults allow the consideration of the innermost retina and
optic nerve as potential sources of nucleotidases secreted
to the vitreous cavity. Moreover, the pathological
neofibrovascular tissue may be considered as yet another
source of secreted ALP, contributing to the increased
levels of this soluble enzyme in PDR eyes.
Discussion
Purinergic signaling has become an area of renewed focus for
both basic research and drug discovery. This study was under-
taken to further elucidate regulatory mechanisms governing
purinergic signaling in the human eye. Major findings are
highlighted in Fig. 7 and can be summarized as follows: (1)
a broad network of purine-converting enzymes was identified
in human vitreous, where it coordinately controls purine levels
through counteracting ATP-inactivating and ATP-
regenerating pathways; (2) DR patients with VH contain high
soluble AK, ADA, eN/CD73, and ALP activities, thus con-
tributing to the maintenance of chronically elevated ATP/
Fig. 4 Soluble purinergic activities correlate with concurrently increased
concentrations of ATP and ADP during diabetic vitreous hemorrhage. VF
were collected from non-diabetic patients with macular hole or pucker
(MH/pucker), as well as from DR patients, which were further sub-
divided into groups of non-hemorrhagic eyes (NH) and eyes with VH.
a Purine concentrations were assayed using enzyme-coupled biolumines-
cent (ATP, ADP) and fluorometric (adenosine) sensing assays and pre-
sented as box-and-whiskers plots (nmol/L). *P < 0.05 and **P < 0.01,
determined by one-way ANOVA with Dunnett’s multiple comparison
test. b Intravitreal purines were further correlated with soluble AK,
eNCD73, ADA, and ALP activities, as indicated. Spearman’s correlation
coefficients (Spearman r) were computed to investigate the relationship
between soluble enzymatic activities and purine concentrations. Raw cor-
relation analysis data for each particular enzyme are shown in
Supplementary Figs. S3-S6. *P < 0.05 and **P < 0.01, determined by
the nonparametric two-tailed correlation analysis
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adenosine ratio; (3) this work additionally points to the selec-
tive distribution of key ecto-nucleotidases (NTPDase1/CD39,
NTPDase2, eN/CD73, and ALP) within certain ocular struc-
tures, including neuroretinal and subretinal layers, the optic
nerve head, and pathological PDR neofibrovascular tissues.
We have recently identified soluble intravitreal enzymes,
eN/CD73 and AK (mainly comprising of the AK1 isoform)
and further demonstrated that AK activity was selectively up-
regulated in PDR eyes, accompanied by concurrently elevated
concentrations of ATP, ADP, angiopoietin-2, TGFβ1, MMP-
9, and other inflammatory and angiogenic factors [17]. The
current study extends the earlier findings by showing that,
along with eN/CD73 and AK, other soluble enzymes
NTPDase/ADPase, ADA, and ALP circulate in the human
vitreous. Strikingly, by dividing the VF based on non-
clearing VH as additional clinical enrollment criteria for
diabetic vitrectomy, we revealed highly specific upregulations
of soluble AK, ADA, eN/CD73, and ALP activities in DR
eyes with VH (see Fig. 3a).
Another salient finding of this study is the identification of
an extensive network of ocular membrane-bound
ectoenzymes. Previous histochemical analyses of human, ca-
nine and rodent eyes have shown a selective distribution of
ecto-nucleotidases in the retinal vasculature (NTPDase1/
CD39) and parenchyma (NTPDase2) [7, 34, 35], as well as
inner Müller cell processes (eN/CD73) [7, 17, 34, 36]. Here,
we have also demonstrated differential localizations of key
ecto-nucleotidases in the human ganglion cells (NTPDase2),
rod-and-cone-containing photoreceptor layer (eN/CD73), the
outer segments of the photoreceptors, retinal vasculature and
the adjacent RPE and choriocapillaris layers (NTPDase1/
CD39) (see Fig. 5). Abundant expression of nucleotide-
Fig. 5 Distribution of ecto-nucleotidases and alkaline phosphatase in the
human neuroretina and PDR fibrovascular tissues. Formalin-fixed,
paraffin-embedded sections of an enucleated human eyeball were stained
with rabbit anti-eN/CD73 (a), α-NTPDase1/CD39 (b), α-NTPDase2 (c),
and α-ALP (d) antibodies, as well as with IgG from rabbit serum as a
negative control (e). Subsequent microscopic examination reveals a se-
lective distribution of key nucleotide-inactivating enzymes on photore-
ceptors, the choriocapillaris and other (sub)retinal structures. f
Neofibrovascular tissues were surgically excised from two PDR patients
and further assayed for ALP activity by using the artificial chromogenic
enzyme substrates BCIP/NBT with subsequent monitoring of the devel-
opment of the blue color reaction. Tissue cryosections were also co-
stained with a rabbit anti-human ALP antibody (cyan) and DAPI (blue),
as well as with hematoxylin and eosin (H&E), as indicated. Scale bars:
200 μm (a–e), 500 μm (f)
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inactivating enzymes in the plane where the retina is cleaved
in the living eye during pathological retinal detachment might
be of particular relevance in terms of preventing excessive
inflammatory responses and maintaining the choroidal and
Fig. 6 The distribution of ecto-nucleotidase activities in the human optic
nerve head. a Hematoxylin and eosin (H&E) staining of transverse cryo-
sections of the human optic nerve head. CRA, central retinal artery; CRV,
central retinal vein; NB, nerve bundles; S, septa; Arac, arachnoid; Dura,
dura mater. b Optic nerve cryosections were pre-incubated with or with-
out specific ALP inhibitor tetramisole (tetra; 2 mM) and subsequently
incubated with the mixture of artificial chromogenic substrates
(BCIP/NBT, 0.35 mM each). A strong ALP-specific dark purple staining
can be seen in the pia mater and connective tissue septa. (c) Lead nitrate-
based histochemical staining of ecto-nucleotidase activities was
performed in the absence (Blank) and presence of nucleotide substrates
ADP (400 μM), ATP (400 μM) and AMP (2 mM), as indicated. (d, e)
Tissue sections were incubated with mouse anti-CD73 (4G4), rabbit anti-
NTPDase2 (hN2-2l), and guinea pig anti-NTPDase1/CD39 (hN1-1c) an-
tibodies and subsequently co-stained with the appropriate secondary
fluorochrome-conjugated immunoglobulins. Nuclei were counterstained
with DAPI (shown in blue on the rightmost merged images). Scale bars:
1 mm (a, left; b, c, left), 200 μm (a, right; c, right, d, e), and 100 μm (b,
inset)
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retinal blood supplies via rapid inactivation of locally released
ATP. In this context, it is relevant to mention that P2X7 recep-
tors expressed on photoreceptor cells can be implicated in
ATP-mediated subretinal hemorrhage, choroidal neovascular-
ization, and photoreceptor cell death [4, 7], while
macrophage/microglial P2X7 seems to act as a scavenger re-
ceptor by clearing debris around the RPE and removing met-
abolic end products from photoreceptors [9].
Data on the specific distribution of ecto-nucleotidases in
the optic nerve head further extend our knowledge on the
regulatory mechanisms of purinergic signaling in the human
eye. In particular, NTPDase1/CD39 was shown to be
expressed in the central retinal artery and other ocular blood
vessels. These findings are consistent with data on the abun-
dant expression of NTPDase1/CD39 on vascular endothelial
cells and its implication in the control of hemostasis through
the termination of pro-inflammatory and pro-thrombotic ef-
fects of intravascular ATP and ADP [31, 32, 37]. By contrast,
nerve bundle-surrounding microglial cells displayed strong
immunoreactivity for NTPDase2. Due to the high preference
of NTPDase2 for the hydrolysis of ATP over ADP [31, 32],
this ectoenzyme presumably has functionality in the rapid
scavenging of mitogenic extracellular nucleoside triphos-
phates in a neuronal environment, while the subsequent deg-
radation of ATP-derived ADP into AMP will occur with con-
siderable delay [38]. The identification of eN/CD73 in the
connective tissue septa surrounding NTPDase2-positive mi-
croglia and NTPDase1/CD39-positive blood vessels suggest
the efficient crosstalk between these ecto-nucleotidases, me-
diating tuned regulation of the ATP-adenosine axis within the
optic nerve-fiber bundles and vasculature.
Tissue-nonspecific ALP is known to play a crucial role in
bone and cartilage mineralization via the maintenance of the
proper concentrations of a powerful mineralization inhibitor
PPi [32, 39] and it has also been identified among the top
calcification-related genes overexpressed in the human trabec-
ular meshwork [40]. Therefore, the selective expression of
ALP in the neurosensory retina and optic nerve head (mainly
restricted to the choriocapillaris, pia mater, and small blood
vessels and capillaries) may be considered as an important and
heretofore unrecognized mechanism controlling blood supply
and soft tissue calcification. Furthermore, the presence of ALP
in the pathological neofibrovascular tissues surgically excised
from PDR eyes (see Fig. 5f), together with data on significant-
ly upregulated soluble ALP activity in DR eyes without and
with VH (see Fig. 3a) provide a novel insight into the role of
this enzyme in the pathogenesis of advanced DR. Though,
given a broad substrate specificity of ALP towards different
phosphate-containing compounds with a pH optimum for this
catalytic reaction lying in the alkaline range [31, 32], further
studies are required to validate the contribution of ALP to the
ocular nucleotide homeostasis.
Data on selective compartmentalization of ecto-
nucleotidases in certain ocular structures, together with the
identification of a wide spectrum of soluble enzymes co-
expressed to a variable extent in human VF, provide novel
insights into the regulatory mechanisms governing the dura-
tion and magnitude of purinergic signaling in a healthy and
diseased eye. Taking into account the fact that the vitreous is
the largest structure within the eye occupying about 80% of
the ocular volume [41], the constitutive presence of soluble
purine-converting enzymes might represent an important aux-
iliary effector system for tuned control of balanced nucleotides
and adenosine levels in the VF. For instance, eN/CD73 is
highly expressed on the photoreceptor cells in human (see
Fig. 5a), canine [36, 42] and rodent [34] retinas, while A2A
receptors are known to be predominantly localized on the
inner nuclear layer and ganglion cells facing towards the
Fig. 7 Ocular purine homeostasis is upregulated in DR eyes with VH.
The cartoon illustrates the fundus of the eye from healthy subjects and
patients with MH, as well as from non-proliferative diabetic retinopathy
(NPDR) eyes and PDR eyes with prolonged non-clearing vitreous hem-
orrhage (VH). VH mainly occurs in PDR eyes, which are characterized
by the invasion of abnormal blood vessels and neovascularization. The
image on the right shows the cross section of the eye and further specifies
the selective distribution of different ecto-nucleotidases in the sensory
retina, blood vessels, and optic nerve head. The scheme highlights ex-
change activities of adenine nucleotides and adenosine in human vitreous.
Soluble eN/CD73, ADA, AK, and ALP activities are up-regulated in
diabetic eyes with VH, thus contributing to the persistent maintenance
of high intravitreal concentrations of pro-inflammatory and angiogenic
ATP
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vitreous lumen [11, 36, 43]. These data indirectly imply an
important physiological contribution of the soluble forms of
eN/CD73 and ADA in controlling local adenosine levels at the
vitreoretinal interface. The identification of soluble AK sug-
gests that regulation of ocular nucleotide homeostasis extends
beyond the inactivating pathways. AK is abundantly present
in the cytosols of well-differentiated tissues with a high-
energy demand [44, 45], including the brain [31, 46], and
rod outer segments of the retina [47], where it regulates ade-
nine nucleotide pools by catalyzing reversible phosphoryl
transfers ATP + AMP ↔ 2ADP. Along with intracellular lo-
calization, this ATP-regenerating enzyme is expressed on the
surface of vascular endothelial and other cells [31, 33] and it
also freely circulates in the human and murine bloodstream
[25, 48], human VF ([17]; current study), and rat pancreatic
juice [49]. Strikingly, the dramatic activation of AK-mediated
phosphotransfer reactions in DR eyes with VH correlates with
concurrently elevated concentrations of ATP and ADP (see
Fig. 4b), thus allowing to consider this soluble enzyme as an
unfavorable factor triggering spatial propagation of ATP-
mediated inflammatory responses into the surrounding retina
far distant from the site of focal detachment.
These findings prompted important questions regarding the
origins of the measured activities and mechanisms underlying
their appearance in the vitreous. It may be speculated that
certain portions of ocular (ecto)enzymes are co-released into
the vitreous cavity, along with ATP and other transmitters, in
response to light-evoked neuronal stimulations, mechanical
perturbations caused by incessant eye movements and varia-
tions in the vascular tone and intraocular pressure. Cellular
mechanisms underlying the release of purinergic enzymes
might particularly involve the shedding of membrane-bound
eN/CD73 and ALP via cleavage of their glycosyl-
phosphatidylinositol anchors, microvesicular shedding, exo-
cytosis, and other secretory pathways [31, 32]. Therefore, in
principle, high soluble activities in the DR eyes might reflect a
global upregulation of membrane-bound ectoenzymes and
their partial shedding into the vitreous lumen. Indeed, the ac-
tivities of ecto-nucleotidases and other components of the
purinergic signaling cascade are known to be activated in the
retina under all pathophysiological conditions investigated so
far [4, 5, 7, 13]. For instance, the expression of A2A receptors
and the activity of eN/CD73 are upregulated in the inner
Müller cell processes during the vasculoproliferative stage of
an experimental model of oxygen-induced retinopathy trig-
gered by a 4-day exposure of neonatal dogs to high oxygen
and their subsequent return to normal air [36]. Though, our
data on markedly activated intravitreal purine homeostasis
only in the DR eyes with severe VH suggest the implication
of more specific mechanisms triggering the release of soluble
enzymes and/or endogenous ATP from the extravascular
blood cells and abnormal blood vessels in the course of retinal
degeneration, blood clotting, and neovascularization.
Collectively, these data provide evidence for selective VH-
related shifts in purine homeostasis in DR eyes from the gen-
eration of anti-inflammatory adenosine towards a pro-
inflammatory and angiogenic ATP-regenerating phenotype.
Identifying the exact mechanisms by which the extensive net-
work of membrane-associated and soluble enzymes regulates
ocular nucleotide and nucleoside concentrations and the fur-
ther translation of purine-converting enzymes as potential
therapeutic targets in the treatment of proliferative retinopa-
thies with VH and other vascular and degenerative eye dis-
eases will be an area of intense interest in the future.
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